BRPI0720023A2 - método para prevenir ou tratar isquemia do miocárdio por inibição da enzima dgat1 com um inibidor de dgat1 - Google Patents

método para prevenir ou tratar isquemia do miocárdio por inibição da enzima dgat1 com um inibidor de dgat1

Info

Publication number
BRPI0720023A2
BRPI0720023A2 BRPI0720023A BRPI0720023A BRPI0720023A2 BR PI0720023 A2 BRPI0720023 A2 BR PI0720023A2 BR PI0720023 A BRPI0720023 A BR PI0720023A BR PI0720023 A BRPI0720023 A BR PI0720023A BR PI0720023 A2 BRPI0720023 A2 BR PI0720023A2
Authority
BR
Brazil
Prior art keywords
dgat1
preventing
myocardial ischemia
inhibiting
enzyme
Prior art date
Application number
BRPI0720023A
Other languages
English (en)
Inventor
Bose Avirup
Edward Hughes Thomas
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0720023A2 publication Critical patent/BRPI0720023A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0720023A 2006-12-11 2007-12-10 método para prevenir ou tratar isquemia do miocárdio por inibição da enzima dgat1 com um inibidor de dgat1 BRPI0720023A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86944806P 2006-12-11 2006-12-11
PCT/US2007/086919 WO2008073865A2 (en) 2006-12-11 2007-12-10 Method of preventing or treating myocardial ischemia

Publications (1)

Publication Number Publication Date
BRPI0720023A2 true BRPI0720023A2 (pt) 2018-09-04

Family

ID=39186851

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720023A BRPI0720023A2 (pt) 2006-12-11 2007-12-10 método para prevenir ou tratar isquemia do miocárdio por inibição da enzima dgat1 com um inibidor de dgat1

Country Status (11)

Country Link
US (1) US20100016387A1 (pt)
EP (1) EP2101783A2 (pt)
JP (1) JP2010512410A (pt)
KR (1) KR20090098877A (pt)
CN (1) CN101600437A (pt)
AU (1) AU2007333234A1 (pt)
BR (1) BRPI0720023A2 (pt)
CA (1) CA2671315A1 (pt)
MX (1) MX2009006171A (pt)
RU (1) RU2009126418A (pt)
WO (1) WO2008073865A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007266890B2 (en) 2006-05-30 2011-02-17 Astrazeneca Ab 1, 3, 4 -oxadiazole derivatives as DGAT1 inhibitors
BRPI0821274A2 (pt) 2007-12-20 2017-06-13 Astrazeneca Ab composto ou um sal, ou pró-droga farmaceuticamente aceitável do mesmo, uso do mesmo, método para tratar uma doença em um animal de sangue quente, e, composição farmacêutica
TW201000099A (en) 2008-06-20 2010-01-01 Amgen Inc S1P1 receptor agonists and use thereof
US20110301192A1 (en) * 2008-10-01 2011-12-08 The Regents Of The University Of California Inhibitors of Cyclin Kinase Inhibitor p21
WO2010108051A2 (en) 2009-03-20 2010-09-23 Ligand Pharmaceuticals Inhibitors of diacylglycerol o-acyltransferase 1(dgat-1) and uses thereof
RU2011152517A (ru) 2009-06-19 2013-07-27 Астразенека Аб Пиразинкарбоксамиды в качестве ингибиторов dgat1
JP2013531037A (ja) * 2010-07-13 2013-08-01 メルク・シャープ・エンド・ドーム・コーポレイション スピロ環式化合物
PT2781516T (pt) * 2010-10-07 2017-03-15 Novartis Ag Novas formas cristalinas do sal de sódio do ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético
CN102988351A (zh) * 2012-11-19 2013-03-27 何晓涛 Aphanamixoid A在制备治疗心肌缺血药物中的应用
JP6252009B2 (ja) * 2013-07-24 2017-12-27 Jnc株式会社 新規ジアミン、これを用いたポリマー、液晶配向剤、液晶配向膜、および液晶表示素子
CA2938311C (en) 2014-02-03 2023-03-07 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ror-gamma
SI3207043T1 (sl) 2014-10-14 2019-04-30 Vitae Pharmaceuticals, Inc. Dihidropirolopiridinovi inhibitorji za ROR-gama
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
WO2016133362A1 (ko) * 2015-02-17 2016-08-25 주식회사 엘지화학 봉지 필름
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
CN108463458B (zh) 2015-11-20 2022-02-01 生命医药有限责任公司 ROR-γ的调节剂
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2019023207A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF RORƳ
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
CN112041311B (zh) 2018-04-19 2023-10-03 吉利德科学公司 Pd-1/pd-l1抑制剂
KR20230159715A (ko) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
AU2019309894A1 (en) 2018-07-27 2021-01-28 Biotheryx, Inc. Bifunctional compounds as CDK modulators
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP2023512116A (ja) * 2020-01-28 2023-03-23 プロテゴ バイオファーマ， インコーポレイテッド トランスサイレチンの安定化及びトランスサイレチンの誤った折り畳みの阻害のための化合物、組成物、及び方法
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU742641B2 (en) * 1998-01-28 2002-01-10 Shionogi & Co., Ltd. Novel tricyclic compound
WO2000025780A1 (en) * 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
AU2003286895A1 (en) * 2002-11-05 2004-06-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases
EP1562956A4 (en) * 2002-11-22 2007-10-10 Japan Tobacco Inc HETEROCYCLES CONTAINING FUSED BICYCLIC NITROGEN
WO2005013907A2 (en) * 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
ES2357015T3 (es) * 2004-10-15 2011-04-15 Bayer Healthcare Llc Preparación y uso de derivados bifenil-4-ilcarbonilaminoácido para el tratamiento de la obesidad.
WO2006064189A1 (en) * 2004-12-14 2006-06-22 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
JPWO2006082952A1 (ja) * 2005-02-01 2008-06-26 武田薬品工業株式会社 アミド化合物
AU2006236155A1 (en) * 2005-04-19 2006-10-26 Bayer Pharmaceuticals Corporation Aryl alkyl acid derivatives for and use thereof
ES2589736T3 (es) * 2006-03-31 2016-11-16 Novartis Ag Derivados de piridina como inhibidores de DGAT

Also Published As

Publication number Publication date
WO2008073865A2 (en) 2008-06-19
CA2671315A1 (en) 2008-06-19
KR20090098877A (ko) 2009-09-17
AU2007333234A1 (en) 2008-06-19
RU2009126418A (ru) 2011-01-20
US20100016387A1 (en) 2010-01-21
MX2009006171A (es) 2009-06-19
WO2008073865A3 (en) 2009-02-12
EP2101783A2 (en) 2009-09-23
CN101600437A (zh) 2009-12-09
JP2010512410A (ja) 2010-04-22

Similar Documents

Publication Publication Date Title
BRPI0720023A2 (pt) método para prevenir ou tratar isquemia do miocárdio por inibição da enzima dgat1 com um inibidor de dgat1
BRPI0619586A2 (pt) método para o tratamento ou prevenção de um distúrbio associado com cd40
DK3178792T3 (da) Fremgangsmåde til aflejringshæmning
DK1981892T3 (da) Thienopyridinderivater som mek-inhibitorer
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
DK2021335T3 (da) Heterocykliske forbindelser som C-FMS-kinasehæmmere
BRPI0717656A2 (pt) Derivados de diaril oxadiazol
BRPI0810541A2 (pt) Método para aumentar o ph de um metrial subsuperficial
BRPI0907174A2 (pt) Métodos para prevenção ou reparação de depósito de xantana
BRPI0913129A2 (pt) método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo
BRPI0905912A2 (pt) "métodos para a detecção de um microorganismo alvo e composição para detecção de microorganismo alvo"
BRPI0915984A2 (pt) método para inibição da corrosão
ZA200809689B (en) 1, 3, 4 -Oxadiazole derivatives as DGAT1 inhibitors
IL194339A0 (en) Enzyme inhibitors
BRPI0718661A2 (pt) Método para prevenir o crescimento de microorganismos, e uma combinação para a prevenção do crescimento microbiano
EP2350266A4 (en) METHOD FOR TREATING OR PREVENTING A PANCREAS DYSFUNCTION
BRPI0722077A2 (pt) Processo para o acabamento de poliolefina
BRPI0716172A2 (pt) instalaÇço de remoÇço de revestimento e mÉtodo para operaÇço da mesma.
BRPI0921354A2 (pt) método para tratamento ou prevenção de trombose usando etexilato de dabigatran ou um sal do mesmo com aprimorada eficácia em relação à terapia convencional com varfarina.
FR2911341B1 (fr) Inhibiteur de corrosion
BRPI0718324A2 (pt) Métodos para o tratamento de depressão.
SI2104497T1 (sl) Derivati sulfamida kot inhibitorji TAFIa
BRPI0919100A2 (pt) Inibição de corrosão.
BRPI0918223A2 (pt) processo para controlar o ph e o nível de íons alvo de uma composição líquida.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]